Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) FCF Margin (2022 - 2025)

Historic FCF Margin for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to 0.58%.

  • Axsome Therapeutics' FCF Margin rose 184500.0% to 0.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 18.07%, marking a year-over-year increase of 211800.0%. This contributed to the annual value of 33.36% for FY2024, which is 204700.0% up from last year.
  • As of Q3 2025, Axsome Therapeutics' FCF Margin stood at 0.58%, which was up 184500.0% from 21.62% recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' FCF Margin peaked at 0.58% during Q3 2025, and registered a low of 382.97% during Q2 2022.
  • Over the past 4 years, Axsome Therapeutics' median FCF Margin value was 39.22% (recorded in 2023), while the average stood at 78.29%.
  • Its FCF Margin has fluctuated over the past 5 years, first surged by 2641700bps in 2023, then tumbled by -651900bps in 2024.
  • Over the past 4 years, Axsome Therapeutics' FCF Margin (Quarter) stood at 113.84% in 2022, then skyrocketed by 63bps to 42.46% in 2023, then soared by 48bps to 22.09% in 2024, then skyrocketed by 103bps to 0.58% in 2025.
  • Its FCF Margin stands at 0.58% for Q3 2025, versus 21.62% for Q2 2025 and 35.99% for Q1 2025.